Breakthrough Bleeding in Transgender and Gender Diverse Adolescents and Young Adults on Long-Term Testosterone
- PMID: 33910088
- DOI: 10.1016/j.jpag.2021.04.004
Breakthrough Bleeding in Transgender and Gender Diverse Adolescents and Young Adults on Long-Term Testosterone
Abstract
Study objective: Amenorrhea is a goal of many transgender and gender diverse adolescent and young adult (TGD AYA) patients on testosterone gender-affirming hormone therapy (T-GAHT). Breakthrough bleeding can contribute to worsening gender dysphoria. Our objective was to evaluate breakthrough bleeding in TGD AYA on T-GAHT.
Design: Institutional review board-approved retrospective cohort.
Setting: Tertiary-care children's hospital.
Participants: TGD AYA on T-GAHT >1 year.
Interventions: None; observational.
Main outcome measures: Presence of, and risk factors for, breakthrough bleeding.
Results: Of the 232 patients who met inclusion criteria, one-fourth (n = 58) had 1 or more episodes of breakthrough bleeding, defined as bleeding after more than 1 year on T-GAHT. In comparing patients with breakthrough bleeding to those without, there were no significant differences between age of initiation, body mass index (BMI), race/ethnicity, testosterone type used, use of additional menstrual suppression, serum testosterone, or estradiol levels. Patients with breakthrough bleeding patients were on T-GAHT longer (37.3 ± 17.0 vs 28.5 ± 14.6 months, P < .001) and were more likely to have endometriosis (P = .049). Breakthrough bleeding began at a mean of 24.3 ± 17.2 months after T-GAHT initiation. Of those with breakthrough bleeding, 46 (79.3%) had no known cause, 10 (17.2%) bled only with missed T-GAHT doses, and 2 (3.4%) bled only when withdrawing from concomitant menstrual suppression. No breakthrough bleeding management method was found to be superior.
Conclusion: Breakthrough bleeding is relatively common (25%) on T-GAHT despite early amenorrhea. Most cases do not have an identifiable cause. Our data did not show superiority of any 1 method for managing breakthrough bleeding on T-GAHT.
Keywords: Abnormal uterine bleeding; Adolescent; Bleeding; Breakthrough bleeding; Menstrual suppression; Testosterone; Trans man; Transgender; Transmasculine; Vaginal bleeding.
Copyright © 2021 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Incidence of breakthrough bleeding in transgender and gender-diverse individuals on long-term testosterone.Am J Obstet Gynecol. 2024 Apr;230(4):434.e1-434.e10. doi: 10.1016/j.ajog.2023.12.036. Epub 2024 Jan 4. Am J Obstet Gynecol. 2024. PMID: 38181830
-
Management of breakthrough bleeding in transgender and gender diverse individuals on testosterone.Am J Obstet Gynecol. 2024 Nov;231(5):534.e1-534.e11. doi: 10.1016/j.ajog.2024.06.004. Epub 2024 Jun 13. Am J Obstet Gynecol. 2024. PMID: 38876414
-
Effects of gender affirming hormone treatment in transgender individuals - a retrospective cohort study.Endocrine. 2024 Jul;85(1):370-379. doi: 10.1007/s12020-024-03736-0. Epub 2024 Feb 22. Endocrine. 2024. PMID: 38386168
-
Fertility in transgender and gender diverse people: systematic review of the effects of gender-affirming hormones on reproductive organs and fertility.Hum Reprod Update. 2025 May 1;31(3):183-217. doi: 10.1093/humupd/dmae036. Hum Reprod Update. 2025. PMID: 39854640
-
Reproductive Health in Trans and Gender Diverse Patients: Effects of transmasculine gender-affirming hormone therapy on future reproductive capacity: clinical data, animal models, and gaps in knowledge.Reproduction. 2024 Oct 3;168(5):e240163. doi: 10.1530/REP-24-0163. Print 2024 Nov 1. Reproduction. 2024. PMID: 39190001 Free PMC article. Review.
Cited by
-
Danazol's use for menstrual suppression in transgender individuals: A retrospective multi-site cohort study.Womens Health (Lond). 2024 Jan-Dec;20:17455057241265081. doi: 10.1177/17455057241265081. Womens Health (Lond). 2024. PMID: 39051650 Free PMC article.
-
Cancer surveillance for transgender and gender diverse patients with Lynch syndrome: a practice resource of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer.Fam Cancer. 2023 Oct;22(4):437-448. doi: 10.1007/s10689-023-00341-4. Epub 2023 Jun 21. Fam Cancer. 2023. PMID: 37341816 Review.
-
Pelvic Pain in Transgender People Using Testosterone Therapy.LGBT Health. 2023 Apr;10(3):179-190. doi: 10.1089/lgbt.2022.0187. Epub 2023 Jan 4. LGBT Health. 2023. PMID: 36603056 Free PMC article.
-
Care for Transgender Young People.Horm Res Paediatr. 2022;95(5):405-414. doi: 10.1159/000524030. Epub 2022 Mar 10. Horm Res Paediatr. 2022. PMID: 35272283 Free PMC article. Review.
-
Transgender and gender diverse individuals embodying endometriosis: a systematic review.Front Med (Lausanne). 2024 Nov 19;11:1430154. doi: 10.3389/fmed.2024.1430154. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39629234 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous